SCHEMBL2761954

SCHEMBL2761954

C=CC(=O)Nc1ccccc1NC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 6/20 0.62
PTPN1 P18031 1/20 0.50
PTPN11 Q06124 1/20 0.50
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
GSTO1 P78417 3/20 0.45
EGFR P00533 2/20 0.45
MMP1 P03956 2/20 0.45
MMP2 P08253 2/20 0.45
MMP9 P14780 2/20 0.45
F13A1 P00488 1/20 0.44
LMNA P02545 1/20 0.44
TGM1 P22735 1/20 0.44
TGM3 Q08188 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31228347 0.92 TGM2 (0.65) TGM2PTPN1PTPN11KDM4EMAPT
SCHEMBL613090 0.92 TGM2 (0.65) TGM2PTPN1PTPN11KDM4EMAPT
SCHEMBL1961608 0.83 TGM2 (0.67) TGM2PTPN1PTPN11KDM4EMAPT
SCHEMBL29519193 0.82 SMN1; SMN2 (0.54) KDM4ELMNAALDH1A1MEN1HPGD
SCHEMBL1226530 0.82 SMN1; SMN2 (0.54) KDM4ELMNAALDH1A1MEN1HPGD
SCHEMBL23653363 0.82 TGM2 (0.55) TGM2PTPN1PTPN11KDM4EMAPT
SCHEMBL17524758 0.82 TGM2 (0.55) TGM2PTPN1PTPN11KDM4EMAPT
SCHEMBL3690870 0.82 TGM2 (0.55) TGM2PTPN1PTPN11KDM4EMAPT
SCHEMBL648951 0.82 NPC1 (0.62) TGM2KDM4EMAPTEGFRMMP1
SCHEMBL19501015 0.82 TGM2 (0.70) TGM2KDM4EMAPTEGFRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220151962-A1 NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2022-05-19 US disclosed
EP-3941900-A1 NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 Deutsches Krebsforschungszentrum (DE) 2022-01-26 EP disclosed
WO-2020193431-A1 NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2020-10-01 WO disclosed
EP-2398769-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094678-A1 NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220151962-A1 NOVEL INHIBITORS OF HISTONE DEACETYLASE 10 HDAC10, HDAC1, HDAC11 TGM2 1182/4885PTPN1 2436/4885PTPN11 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.